⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20888424 | 0.75 | — | — | |
| SCHEMBL4375559 | 0.75 | — | — | |
| SCHEMBL1721255 | 0.75 | — | — | |
| SCHEMBL503249 | 0.75 | — | — | |
| SCHEMBL15633375 | 0.75 | — | — | |
| SCHEMBL29547414 | 0.75 | — | — | |
| SCHEMBL34470086 | 0.75 | — | — | |
| SCHEMBL4827826 | 0.75 | — | — | |
| SCHEMBL781323 | 0.72 | — | — | |
| SCHEMBL29384015 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116134018-A | 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4168393-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20210403457-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021257490-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| EP-2010493-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |